According to a systematic review published following PRISMA 2020 standards and registered in PROSPERO under reference ID CRD42026142549, mefloquine—a widely used antimalarial medication—is linked to a broad spectrum of neuropsychiatric adverse effects. The research, which analyzed 25 studies including 17 case reports and 8 clinical studies, found that patients experienced psychological symptoms ranging from mild anxiety and insomnia to severe psychosis, hallucinations, mania, and suicidal ideation.
Understanding the Neuropsychiatric Toxicity Profile of Mefloquine
Mefloquine’s high lipophilicity allows it to easily penetrate the blood-brain barrier, which experimental studies suggest may lead to GABAergic interneuron dysfunction, an imbalance between excitatory and inhibitory neurotransmission, and the prevention of gap junction contact.
Did you know? Mefloquine has an extended elimination half-life ranging from approximately two to four weeks, a pharmacokinetic trait that helps explain why psychiatric symptoms can persist or appear weeks to months after a patient stops taking the medication.
The systematic review highlights distinct differences in how clinical trials and individual case reports document mefloquine’s psychiatric safety profile. While 17 case reports detailing patients captured severe, rare presentations like acute confusion, paranoia, depersonalization, and major depressive disorder with psychosis, the eight clinical studies tracked broader population trends. For instance, randomized controlled trials like the MAL30010 trial evaluated by van Riemsdijk et al. (2002) found clinically significant variations when comparing mefloquine users against alternative regimens like atovaquone plus chloroguanide or atovaquone-proguanil.
| Study Type | Sample Size Range | Key Documented Symptoms |
|---|---|---|
| Randomized Controlled Trials & Cohorts | Anxiety, insomnia, nightmares, dizziness, vivid dreams, depression | |
| Case Reports & Series | Individual patients (ages 7 to 63) | Hallucinations, acute psychosis, mania, suicidal impulses, delirium |
Risk Factors and Patient Screening Recommendations
Medical professionals must carefully evaluate patient history before prescribing chemoprophylaxis or malaria treatment. According to prospective cohort data from van Riemsdijk et al. (2004), individual physiological factors such as a low body mass index (BMI) in women may correlate with an increased risk of neuropsychiatric adverse events and concentration impairment. While severe reactions occur in individuals with no prior mental health history, obtaining a complete psychiatric history remains an essential clinical step to identify vulnerability to depression, anxiety disorders, or psychosis.
Pro Tip: Clinicians should explicitly advise travelers and military personnel to monitor for early warning signs—including strange nightmares, sudden mood swings, or insomnia—and instruct them to discontinue the drug and seek immediate medical evaluation if these symptoms arise.
Frequently Asked Questions
What are the most common neuropsychiatric side effects of mefloquine?
The most frequently reported symptoms include insomnia, abnormal dreams, anxiety, dizziness, irritability, mood swings, depression, and hallucinations.
Why do mefloquine side effects sometimes appear weeks after stopping the medication?
Due to mefloquine’s extended elimination half-life of roughly two to four weeks, the drug remains active in the body long after the final dose, contributing to delayed symptom onset.
How do clinical trials compare mefloquine to other antimalarial drugs?
Randomized controlled trials generally show a higher frequency of neuropsychiatric side effects among individuals taking mefloquine compared to alternative regimens such as atovaquone-proguanil.
Take Action and Stay Informed
Navigating public health and travel medicine requires up-to-date, evidence-based insights. Explore our travel health archive for more systematic breakdowns of antimalarial safety profiles, or subscribe to our weekly newsletter to receive the latest clinical reviews directly in your inbox.
Keep reading